Details for Patent: 10,835,515

Which drugs does patent 10,835,515 protect, and when does it expire?

Patent 10,835,515 protects NUBEQA and is included in one NDA.

This patent has fourteen patent family members in twelve countries.

Summary for Patent: 10,835,515

Title:	Carboxamide derivative and its diastereomers in stable crystalline form
Abstract:	The present disclosure relates to solid crystalline forms of N--((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-- hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament. ##STR00001##
Inventor(s):	Tormakangas; Olli (Turku, FI), Heikkinen; Terhi (Lieto, FI)
Assignee:	ORION CORPORATION (Espoo, FI)
Application Number:	16/458,435
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,835,515

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes			Y			TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Foreign Priority and PCT Information for Patent: 10,835,515

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Finland	20150033	Jan 30, 2015

International Family Members for US Patent 10,835,515

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	3250554
European Patent Office	3250554
Spain	2917549
Croatia	P20220998
Hungary	E058986
Japan	2018503662